Related Experiment Video

Updated: Jul 4, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

[Target selectivity of anticancer drugs]

S I S Fattoruso1, L Di Lauro, F Conti

  • 1Istituto Nazionale Tumori Regina Elena, Roma.

La Clinica Terapeutica
|July 3, 2008
PubMed

Insights

Developing targeted cancer therapies is crucial. Future strategies focus on multitargeted agents and phase 0 clinical trials for personalized cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Context:

  • Chemotherapy, while foundational in cancer treatment, often yields palliative effects rather than cures.
  • Advances in understanding cancer genetics have led to targeted therapies with significant success in specific cases (e.g., imatinib for GIST).
  • Tumorigenesis typically involves multiple genetic alterations, necessitating novel therapeutic strategies.

Purpose:

  • To explore the evolution of anticancer drug development from traditional chemotherapy to molecularly targeted agents.
  • To highlight the limitations of single-target therapies and advocate for multitargeted approaches.
  • To introduce phase 0 clinical trials as a method for enhancing drug selectivity and patient stratification.

Summary:

  • Current anticancer drug development is shifting from broad-spectrum chemotherapy towards agents targeting specific molecular pathways.
  • The complexity of cancer, driven by multiple genetic changes, suggests that multitargeted therapies may offer superior efficacy.
  • Phase 0 clinical trials represent a promising avenue for improving the precision of anticancer drug selection and patient matching.

Impact:

  • This research informs the development of more effective and personalized cancer treatments.
  • It emphasizes the need for a deeper understanding of tumor molecular profiles to guide therapeutic decisions.
  • The findings support the integration of innovative trial designs like phase 0 studies to accelerate the discovery of optimal cancer therapies.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...